Skip to main content
Back
Watch Compare

GALECTIN THERAPEUTICS INC

Data quality: 83%
GALT
Nasdaq Manufacturing Chemicals
$2.41
▲ $0.19 (8.56%)
Mkt Cap: 158.64 M
Price
$2.41
Mkt Cap
158.64 M
Day Range
$2.21 — $2.41
52-Week Range
$1.21 — $7.13
Volume
273,728
Open $2.21
50D / 200D Avg
$2.94
18.07% below
50D / 200D Avg
$3.96
39.07% below

Quick Summary

Key Takeaways

Negative free cash flow of -23.88 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.09
Interest Coverage-2.74

Valuation

PE (TTM)
-5.14
Below sector avg (-1.98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E -5.1 -2.0
P/B — 5.1
ROE % — -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

ETFs Holding This Stock

MEDX logo MEDX Horizon Kinetics Medical ETF
1.27% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -30.84 M
ROE N/A ROA -216.64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23.88 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.09
Interest Coverage -2.74 Asset Turnover N/A
Working Capital -123.72 M Tangible Book Value -125.30 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5.14 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15.05%
Market Cap 158.64 M Enterprise Value 147.12 M
Per Share
EPS (Diluted TTM) -0.48 Revenue / Share N/A
FCF / Share -0.36 OCF / Share -0.36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 77.43%
SBC-Adj. FCF -25.85 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -30.84 M -47.05 M -41.07 M -38.78 M -30.53 M
EPS (Diluted) -0.48 -0.76 -0.74 -0.65 -0.52
Gross Profit — — — — —
Operating Income -20.09 M -42.43 M -38.07 M -38.35 M -30.18 M
EBITDA — — — — —
R&D Expenses 14.29 M 36.57 M 32.13 M 31.74 M 23.82 M
SG&A Expenses — — — — —
D&A — 0.0 0.0 0.0 0.0
Interest Expense 7.33 M 5.54 M 2.79 M 1.03 M 489,000.0
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.53 M 17.50 M 28.20 M 21.29 M 41.83 M
Total Liabilities 145.73 M 120.57 M 88.44 M 53.48 M 39.21 M
Shareholders' Equity -127.92 M -104.79 M -61.96 M -33.92 M 893,000.0
Total Debt — — — — —
Cash & Equivalents 17.72 M 15.12 M 25.66 M 18.59 M 39.65 M
Current Assets 19.44 M 17.25 M 27.71 M 20.55 M 41.82 M
Current Liabilities 8.03 M 35.41 M 15.68 M 13.01 M 9.03 M